Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3)
High-throughput screening of a small-molecule library identified a 5-triazolo-2-arylpyridazinone as a novel inhibitor of the important glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3). Such inhibitors are of interest due to PFKFB3's control of the important glycolytic pathway used by cancer cells to generate ATP. A series of analogues was synthesized to study structure-activity relationships key to enzyme inhibition. Changes to the triazolo or pyridazinone rings were not favoured, but limited-size substitutions on the aryl ring provided modest increases in potency against the enzyme. Selected analogues and literature-described inhibitors were evaluated for their ability to suppress the glycolytic pathway, as detected by a decrease in lactate production, but none of these compounds demonstrated such suppression at non-cytotoxic concentrations.
|ISBN||1464-3391 (Electronic) 0968-0896 (Linking)|
|Authors||Brooke, D. G.; van Dam, E. M.; Watts, C. K.; Khoury, A.; Dziadek, M. A.; Brooks, H.; Graham, L. J.; Flanagan, J. U.; Denny, W. A.;|
|Publisher Name||BIOORGANIC & MEDICINAL CHEMISTRY|
|Published Date||2014-01-01 00:00:00|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/24398380|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/12318|